Handelsavisen
prelaunch
Companies ›Consumer Cyclicals ›ESPR.NS
ES
ESPR.NS — NSE (India) Construction Supplies & Fixtures

Espr.Ns

$73,00
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
8,6 %
ROE
11,8 %
Net margin
4,9 %
Debt / equity
0,74
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$3,18
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About

ESPR.NS operates in the construction supplies and fixtures industry, providing products and services that support infrastructure and building projects.

Business. Esperion Therapeutics, Inc. (ESPR) is a pharmaceutical company operating within the Healthcare sector, specifically focused on pharmaceuticals and medical research. The firm generates revenue through the sale of products and is headquartered in the United States. Its common stock is listed on the Nasdaq stock exchange. The company does not report distinct operating segments or geographic breakdowns in the provided data.

Classification92 %
SectorConsumer Cyclicals
Business sectorCyclical Consumer Products
IndustryConstruction Supplies & Fixtures
Generated · model-assisted
Sell-side consensus
HOLD5 analysts
0 buy5 hold0 sell
Avg 12m price target2,85

Analyst recommendations

5 analysts · consensus Hold
Buy0
Hold5
Sell0
12-month price target
2,85
Consensus of sell-side coverage.
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Hold
5 analysts · indicative
Ownership→
JONES FINANCIAL COMPANIES LLLP
largest disclosed fund holder
Profitability→
11,8 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning ESPR.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary · THIS SECTOR+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to ESPR.NS. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    Briefing · model-assisted

    Esperion Therapeutics, Inc. (ESPR) has recorded a notable addition to its shareholder base, marking the first analysis for this ticker with no prior basis for delta computation. This initial snapshot highlights a specific institutional move that serves as the primary signal for the company's current market profile. The material change involves an investor, identified by ID 466, adding a position in Esperion Therapeutics. As of June 30, 2024, this investor holds 2,046,000 shares, representing a value of approximately $1.89 million. This acquisition constitutes a weight of roughly 0.000043% of the total, indicating a focused but relatively small stake in the broader context of the company's equity. This activity is significant as it establishes the baseline for tracking institutional interest in Esperion. With 24 top holders currently identified, the entry of this new investor adds to the diversity of the shareholder base. The lack of prior data means this addition is the first observable shift in ownership structure available for analysis. Esperion Therapeutics operates with a lean executive structure, reporting only one officer, and currently has no analyst coverage or index membership. The absence of analyst estimates and index inclusion suggests the stock may be less scrutinized by mainstream financial markets, making individual holder movements like this one more distinct indicators of sentiment. The company's profile remains defined by its specific holder composition rather than broad market metrics.

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Esperion Therapeutics, Inc. (ESPR) is a pharmaceutical company operating within the Healthcare sector, specifically focused on pharmaceuticals and medical research. The firm generates revenue through the sale of products and is headquartered in the United States. Its common stock is listed on the Nasdaq stock exchange. The company does not report distinct operating segments or geographic breakdowns in the provided data.

    Classification92 %
    SectorConsumer Cyclicals
    Business sectorCyclical Consumer Products
    IndustryConstruction Supplies & Fixtures
    AI synthesis
    GENERATED

    The company maintains a debt-to-equity ratio of 0.74, indicating a moderate reliance on debt financing, and a current ratio of 1.31, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints.

    In terms of profitability, ESPR.NS reports a return on equity (ROE) of 11.75% and a return on assets (ROA) of 5.06%. These figures are to be compared against the industry's preferred metrics and cohort medians to assess relative performance.

    The company's revenue is not segmented by product or geographic region in the provided data, so it is not possible to determine the concentration of revenue across segments or regions.

    The company's growth trajectory is not explicitly detailed in the provided data, but the capital expenditure of -129,253,000 INR suggests a reduction in investment in long-term assets, which may affect future growth.

    The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could affect its ability to meet short-term obligations.

    There are no recent events or filings mentioned in the provided data that would impact the company's operations or financial status.

    Esperion Therapeutics, Inc. (ESPR) has recorded a notable addition to its shareholder base, marking the first analysis for this ticker with no prior basis for delta computation. This initial snapshot highlights a specific institutional move that serves as the primary signal for the company's current market profile. The material change involves an investor, identified by ID 466, adding a position in Esperion Therapeutics. As of June 30, 2024, this investor holds 2,046,000 shares, representing a value of approximately $1.89 million. This acquisition constitutes a weight of roughly 0.000043% of the total, indicating a focused but relatively small stake in the broader context of the company's equity. This activity is significant as it establishes the baseline for tracking institutional interest in Esperion. With 24 top holders currently identified, the entry of this new investor adds to the diversity of the shareholder base. The lack of prior data means this addition is the first observable shift in ownership structure available for analysis. Esperion Therapeutics operates with a lean executive structure, reporting only one officer, and currently has no analyst coverage or index membership. The absence of analyst estimates and index inclusion suggests the stock may be less scrutinized by mainstream financial markets, making individual holder movements like this one more distinct indicators of sentiment. The company's profile remains defined by its specific holder composition rather than broad market metrics.

    Key takeaways
    • ESPR.NS has a moderate debt-to-equity ratio and a current ratio that suggests it can cover its short-term liabilities.
    • The company's ROE and ROA are positive, but their relative performance against industry medians is not provided.
    • The company's capital expenditure is negative, indicating a reduction in investment in long-term assets.
    • The company faces a medium liquidity risk and a low dilution risk.
    • The company's revenue is not segmented, so the concentration of revenue across segments or regions is unknown.
    • There are no recent events or filings that would impact the company's operations or financial status.
    • margin_outlook_rationale: The company's gross profit margin is not explicitly provided, but the gross profit of 1,007,698,000 INR suggests a positive margin.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 3

    Revenue grew at a 69% CAGR from FY2023 to FY2025, demonstrating strong top-line expansion momentum.

    The company achieved positive operating income of $60.3 million in FY2025, marking a significant improvement from prior losses.

    Liquidity risk is assessed as low, suggesting the company maintains sufficient short-term financial stability.

    BEAR CASE · 1

    Dilution risk is rated as medium, posing a potential threat to existing shareholder value.

    In focus — financials by report

    Valuation

    Market price
    $73,00
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    $1.33B
    Net cashⓘ
    -$982.0M
    Current ratioⓘ
    1.3
    Debt / equityⓘ
    0.7
    ROAⓘ
    5.1%
    ROEⓘ
    11.8%
    Cash conversionⓘ
    43.0%
    CapEx / revenueⓘ
    -4.0%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    Business relationships5 disclosed relationships · 1 type · extracted from filings & disclosures
    Partners5
    Csl LtdCSL.AXPartner95%Source ↗
    Neopharm Co Ltd092730.KQPartner95%Source ↗
    Pfizer IncPFE.TOPartner90%Source ↗

    Supply chain

    Vendors → ESPR ↔ Partners → Customers · click any node to drill
    VENDORSPARTNERSCUSTOMERSESPRESPREspr.Ns5 entitiesCsl LtdDiversified ConstructionAUDaiichi Sankyo Co LtdOil & Gas Exploration & JPHLS THERAPEUTICS INC.PharmaceuticalsCANeopharm Co LtdPersonal ProductsKRPfizer IncPharmaceuticalsCA
    5 mentions in 10-K0 from corporate websites0 from news dispatches
    Updated 2026-07-13

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 33 %
    EPS
    Consensus EPS
    -0,09
    Predicted surprise
    -0,04
    Beat probability
    33 %
    Analysts
    5
    Other metrics
    Revenue
    —
    no estimate
    Segment revenue
    —
    no estimate
    Margin
    —
    no estimate
    Segment margin
    —
    no estimate
    as of 2026-07-13 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Corporate eventM&A horizon
    M&A probabilityconf 5 %
    Probability
    5 %
    Base rate
    3 %
    Band
    —
    180-day horizon · target 2027-01-23 · 1,8× base rate
    No acquirer candidates identified by the signal model.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$1,78
    Mean$2,85
    Median$3,16
    High$3,28
    Spot$73,00
    −96.1 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin8,6 %Above median
    Net Margin4,9 %Above median
    ROE11,8 %Above P75
    Capex / Rev-4,0 %Above median
    D/E0,74Bottom quartile
    Cash Conv0,43Below median

    Corporate actions / M&A

    M&A probabilityconf —
    Probability
    5 %
    Base rate
    3 %
    Band
    Moderate
    180-day horizon · target 2027-01-23 · 1,8× base rate
    No acquirer candidates identified by the signal model.
    Corporate actionsNo corporate-action source connected yet — splits, dividends and buyback events are not tracked for this company. Honest-dim (no data fabricated).

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net disposed 2 158 540 sh4 grants9 insiders
    • CARROLL J MARTINDirector · Stock Option (right to buy) → Common StockDisposed 32 500 @ $2,25disposition · 2026-07-13
    • Hoffman Robert E.Director · Stock Option (right to buy) → Common StockDisposed 40 000 @ $1,41disposition · 2026-07-13
    • Hoffman Robert E.Director · Stock Option (right to buy) → Common StockDisposed 7 040 @ $0,87disposition · 2026-07-13
    • CARROLL J MARTINDirector · Stock Option (right to buy) → Common StockDisposed 21 000 @ $1,37disposition · 2026-07-13
    • Shepard JayDirector · Stock Option (right to buy) → Common StockDisposed 44 000 @ $0,87disposition · 2026-07-13
    • Shepard JayDirector · Stock Option (right to buy) → Common StockDisposed 32 500 @ $2,25disposition · 2026-07-13
    • Shepard JayDirector · Stock Option (right to buy) → Common StockDisposed 21 000 @ $1,37disposition · 2026-07-13
    • CARROLL J MARTINDirector · Stock Option (right to buy) → Common StockDisposed 44 000 @ $0,87disposition · 2026-07-13
    • Fischer Seth H. Z.Director · Stock Option (right to buy) → Common StockDisposed 21 000 @ $1,37disposition · 2026-07-13
    • Looker BenjaminChief Legal Officer · Stock Option (right to buy) → Common StockDisposed 201 000 @ $1,50disposition · 2026-07-13
    • Looker BenjaminChief Legal Officer · Stock Option (right to buy) → Common StockDisposed 269 230 @ $2,44disposition · 2026-07-13
    • Halladay BenjaminChief Financial Officer · Stock Option (right to buy) → Common StockDisposed 200 000 @ $2,05disposition · 2026-07-13
    • Halladay BenjaminChief Financial Officer · Stock Option (right to buy) → Common StockDisposed 213 000 @ $1,50disposition · 2026-07-13
    • Koenig Sheldon L.Director, President and CEO · Stock Option (right to buy) → Common StockDisposed 647 460 @ $2,44disposition · 2026-07-13
    • Koenig Sheldon L.Director, President and CEO · Stock Option (right to buy → Common StockDisposed 753 000 @ $1,50disposition · 2026-07-13
    • Koenig Sheldon L.Director, President and CEO · Stock Option (right to buy) → Common StockDisposed 642 000 @ $2,05disposition · 2026-07-13
    • Halladay BenjaminChief Financial Officer · Stock Option (right to buy) → Common StockDisposed 221 270 @ $2,44disposition · 2026-07-13
    • THOMPSON JOHN CRAIGDirector · Stock Option (right to buy) → Common StockDisposed 40 000 @ $1,00disposition · 2026-07-13
    • Fischer Seth H. Z.Director · Stock Option (right to buy) → Common StockDisposed 44 000 @ $0,87disposition · 2026-07-13
    • Fischer Seth H. Z.Director · Stock Option (right to buy) → Common StockDisposed 32 500 @ $2,25disposition · 2026-07-13
    • Looker BenjaminChief Legal Officer · Stock Option (right to buy) → Common StockDisposed 150 000 @ $2,05disposition · 2026-07-13
    • Koenig Sheldon L.Director, President and CEO · Stock Option (right to buy) → Common StockAcquired 647 460 @ $2,44grant · 2026-03-13
    • Halladay BenjaminChief Financial Officer · Stock Option (right to buy) → Common StockAcquired 221 270 @ $2,44grant · 2026-03-13
    • Looker BenjaminChief Legal Officer · Stock Option (right to buy) → Common StockAcquired 269 230 @ $2,44grant · 2026-03-13
    • Harlow John B. Jr.Chief Commercial Officer · Stock Option (right to buy) → Common StockAcquired 380 000 @ $3,79grant · 2025-12-04

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • ESPR.NS Market data — financials · 2026-05-27

    Ownership & reference

    Top holders

    • JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$6M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$12M
    • Nuveen LLCInvestment Managers · as of 2024-12-310,00 %$7M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$16M
    • Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$7M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$55M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$6M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$19M
    • Principal Global Investors (Equity)Investment Managers · as of 2026-03-310,00 %$1M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$7M
    • AQR Capital Management, LLCInvestment Managers · as of 2026-03-310,00 %$1M
    • Wellington Management Company, LLPInvestment Managers · as of 2026-03-310,00 %$2M
    • AllianceBernstein L.P.Investment Managers · as of 2026-03-310,00 %$1M
    • Invesco QQQ TrustFunds · as of 2026-03-310,00 %$2M
    • Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$2M
    • Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$2M
    • LPL Financial LLCInvestment Managers · as of 2026-03-310,00 %$1M
    • Franklin Advisers, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Raymond James & Associates, Inc.Brokerage Firms · as of 2026-03-310,00 %$0M
    • FMR LLCInstitutional Investor · as of 2026-03-310,00 %$1M
    • Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$0M
    • Victory Capital Management Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$2M

    Leadership

    • Sheldon L. KoenigPresident, Chief Executive Officer, Director

    Insider activity

    Net selling0 buys · 14 sellsnet -$695K9 insiders · last 365d
    • Fischer Seth H. Z.Director · Common StockOther 141 023 · 2026-07-13
    • Koenig Sheldon L.Director, President and CEO · Common StockOther 2 121 094 · 2026-07-13
    • Halladay BenjaminChief Financial Officer · Common StockOther 705 410 · 2026-07-13
    • Looker BenjaminChief Legal Officer · Common StockOther 667 524 · 2026-07-13
    • Harlow John B. Jr.Chief Commercial Officer · Common StockOther 424 536 · 2026-07-13
    • THOMPSON JOHN CRAIGDirector · Common StockOther 79 873 · 2026-07-13
    • Shepard JayDirector · Common StockOther 164 472 · 2026-07-13
    • CARROLL J MARTINDirector · Common StockOther 177 523 · 2026-07-13
    • Hoffman Robert E.Director · Common StockOther 85 153 · 2026-07-13
    • Looker BenjaminChief Legal Officer · Common StockSold 11 824 @ $3,15$37K · 2026-06-17
    • Halladay BenjaminChief Financial Officer · Common StockSold 10 773 @ $3,15$34K · 2026-06-17
    • Koenig Sheldon L.Director, President and CEO · Common StockSold 53 588 @ $3,15$169K · 2026-06-17
    • Hoffman Robert E.Director · Common StockOther 79 873 · 2026-05-28
    • CARROLL J MARTINDirector · Common StockOther 79 873 · 2026-05-28
    • THOMPSON JOHN CRAIGDirector · Common StockOther 79 873 · 2026-05-28
    • Shepard JayDirector · Common StockOther 79 873 · 2026-05-28
    • Fischer Seth H. Z.Director · Common StockOther 79 873 · 2026-05-28
    • Looker BenjaminChief Legal Officer · Common StockSold 5 708 @ $2,70$15K · 2026-03-17
    • Halladay BenjaminChief Financial Officer · Common StockSold 6 424 @ $2,71$17K · 2026-03-17
    • Koenig Sheldon L.Director, President and CEO · Common StockSold 25 578 @ $2,72$70K · 2026-03-17
    • Looker BenjaminChief Legal Officer · Common StockOther 300 840 · 2026-03-13
    • Koenig Sheldon L.Director, President and CEO · Common StockOther 723 760 · 2026-03-13
    • Halladay BenjaminChief Financial Officer · Common StockOther 247 430 · 2026-03-13
    • Looker BenjaminGeneral Counsel · Common StockSold 1 689 @ $2,88$5K · 2026-01-20
    • Koenig Sheldon L.Director, President and CEO · Common StockSold 48 244 @ $3,67$177K · 2025-12-17

    Short positioning

    17.4Mshares short-16.0% vs prior
    1.74days to cover
    13.2%short of daily vol
    43.3Kfails-to-deliver
    as of 2026-06-30 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    ESPR.NSCanonical
    NSE (India) · USD

    Intel & risk

    PredictorBeat prob33 %Surprise-0,04M&A prob5 %Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.
    Relationship graph
    ESPRCSL.AX4568.THLS.TO092730.KPFE.TOConstruction S
    This companySectorPartners

    Evidence & claims

    From filings & derived data
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): 10.8%Derived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): 56.2%Derived (calculated)
    • EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 60.7%Derived (calculated)
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 4.8%Derived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): 35.5%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 22.3%Derived (calculated)
    • Revenue (YoY) (2025-12-31 vs 2024-12-31): 21.3%Derived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 60.7%Derived (calculated)
    • Net margin (FY 2025-12-31): -5.6%Derived (calculated)
    • Return on equity (FY 2025-12-31): 7.5%Derived (calculated)
    • Return on assets (FY 2025-12-31): -4.9%Derived (calculated)
    • Current ratio (FY 2025-12-31): 1.54xDerived (calculated)
    • Debt-to-equity (FY 2025-12-31): -2.54xDerived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 44.6%Derived (calculated)
    • Capex (YoY) (2025-12-31 vs 2024-12-31): -100.0%Derived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 16.0%Derived (calculated)
    • Total assets (annual): USD 465.89MSEC XBRL filing
    • Operating cash flow (annual): USD -13.09MSEC XBRL filing
    • Current liabilities (annual): USD 300.81MSEC XBRL filing
    • Total liabilities (annual): USD 767.85MSEC XBRL filing
    • Operating income (annual): USD 60.27MSEC XBRL filing
    • EPS (diluted) (annual): USD-PER-SHARES -0SEC XBRL filing
    • Shareholders' equity (annual): USD -301.96MSEC XBRL filing
    • Capex (annual): USD 0SEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-07-13 22:24 UTCFILINGMaterial 8-K
    2026-07-13INSIDERShepard Jay transacted 164.5k sh — Director
    2026-07-13INSIDERHoffman Robert E. transacted 85.2k sh — Director
    2026-07-13INSIDERCARROLL J MARTIN transacted 177.5k sh — Director
    2026-07-13INSIDERFischer Seth H. Z. transacted 141.0k sh — Director
    2026-07-13INSIDERTHOMPSON JOHN CRAIG transacted 79.9k sh — Director
    2026-07-13INSIDERHarlow John B. Jr. transacted 424.5k sh — Chief Commercial Officer
    2026-07-13INSIDERLooker Benjamin transacted 667.5k sh — Chief Legal Officer
    2026-07-13INSIDERHalladay Benjamin transacted 705.4k sh — Chief Financial Officer
    2026-07-13INSIDERKoenig Sheldon L. transacted 2.12M sh — Director, President and CEO
    2026-07-13INSIDERHoffman Robert E. disposed of 40.0k sh Stock Option (right to buy) — Director
    2026-07-13INSIDERHoffman Robert E. disposed of 7.0k sh Stock Option (right to buy) — Director
    2026-07-13INSIDERCARROLL J MARTIN disposed of 21.0k sh Stock Option (right to buy) — Director
    2026-07-13INSIDERCARROLL J MARTIN disposed of 32.5k sh Stock Option (right to buy) — Director
    2026-07-13INSIDERCARROLL J MARTIN disposed of 44.0k sh Stock Option (right to buy) — Director
    2026-07-13INSIDERShepard Jay disposed of 21.0k sh Stock Option (right to buy) — Director
    2026-07-13INSIDERShepard Jay disposed of 32.5k sh Stock Option (right to buy) — Director
    2026-07-13INSIDERShepard Jay disposed of 44.0k sh Stock Option (right to buy) — Director
    2026-07-13INSIDERFischer Seth H. Z. disposed of 44.0k sh Stock Option (right to buy) — Director
    2026-07-13INSIDERFischer Seth H. Z. disposed of 21.0k sh Stock Option (right to buy) — Director
    2026-07-13INSIDERFischer Seth H. Z. disposed of 32.5k sh Stock Option (right to buy) — Director
    2026-07-13INSIDERTHOMPSON JOHN CRAIG disposed of 40.0k sh Stock Option (right to buy) — Director
    2026-07-13INSIDERLooker Benjamin disposed of 150.0k sh Stock Option (right to buy) — Chief Legal Officer
    2026-07-13INSIDERLooker Benjamin disposed of 201.0k sh Stock Option (right to buy) — Chief Legal Officer
    2026-07-13INSIDERLooker Benjamin disposed of 269.2k sh Stock Option (right to buy) — Chief Legal Officer
    2026-07-13INSIDERHalladay Benjamin disposed of 200.0k sh Stock Option (right to buy) — Chief Financial Officer
    2026-07-13INSIDERHalladay Benjamin disposed of 213.0k sh Stock Option (right to buy) — Chief Financial Officer
    2026-07-13INSIDERHalladay Benjamin disposed of 221.3k sh Stock Option (right to buy) — Chief Financial Officer
    2026-07-13INSIDERKoenig Sheldon L. disposed of 642.0k sh Stock Option (right to buy) — Director, President and CEO
    2026-07-13INSIDERKoenig Sheldon L. disposed of 753.0k sh Stock Option (right to buy — Director, President and CEO
    2026-07-13INSIDERKoenig Sheldon L. disposed of 647.5k sh Stock Option (right to buy) — Director, President and CEO
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: insider_flow_signal (90d)
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: ma_probability (180d)
    2026-06-28 03:14 UTCHOLDERInstitutional holding changed
    2026-06-28 03:14 UTCHOLDER1 institutional position change flagged
    2026-06-17 00:00 UTCINSIDER3 insider transactions — 2026-06 · net sell $240k
    2026-06-17 00:00 UTCINSIDER3 insider transactions — 2026-06 · net sell $240k
    2026-06-17INSIDERLooker Benjamin sold 11.8k sh — Chief Legal Officer ~$37k
    2026-06-17INSIDERHalladay Benjamin sold 10.8k sh — Chief Financial Officer ~$34k
    Showing the 40 most recent of 66 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage